305 related articles for article (PubMed ID: 12466028)
1. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
Pancheri P; Scapicchio P; Chiaie RD
Int J Neuropsychopharmacol; 2002 Dec; 5(4):287-94. PubMed ID: 12466028
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
Delle Chiaie R; Pancheri P; Scapicchio P
Am J Clin Nutr; 2002 Nov; 76(5):1172S-6S. PubMed ID: 12418499
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10.
Vorbach EU; Arnoldt KH; Hübner WD
Pharmacopsychiatry; 1997 Sep; 30 Suppl 2():81-5. PubMed ID: 9342765
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
10. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
[TBL] [Abstract][Full Text] [Related]
11. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
Lopez-Ibor JJ; Conesa A;
Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder.
Montgomery SA; Feighner JP; Sverdlov L; Shrivastava RK; Cunningham LA; Kiev A; Hlavka J; Tonelli G
Int J Neuropsychopharmacol; 2006 Oct; 9(5):517-28. PubMed ID: 16259645
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial.
Forlenza OV; Almeida OP; Stoppe A; Hirata ES; Ferreira RCR
Int Psychogeriatr; 2001 Mar; 13(1):75-84. PubMed ID: 11352337
[TBL] [Abstract][Full Text] [Related]
16. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
Katona C; Bercoff E; Chiu E; Tack P; Versiani M; Woelk H
J Affect Disord; 1999 Oct; 55(2-3):203-13. PubMed ID: 10628889
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine.
Berlanga C; Ortega-Soto HA; Ontiveros M; Senties H
Psychiatry Res; 1992 Dec; 44(3):257-62. PubMed ID: 1289923
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R
Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
[TBL] [Abstract][Full Text] [Related]
20. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
Behnke K; Søgaard J; Martin S; Bäuml J; Ravindran AV; Agren H; Vester-Blokland ED
J Clin Psychopharmacol; 2003 Aug; 23(4):358-64. PubMed ID: 12920411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
